Trial Profile
A Mechanistic Pilot Open-label Study to Evaluate the Effect of Benralizumab on Airway Function and Inflammation in Patients With Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 May 2023
Price :
$35
*
At a glance
- Drugs Benralizumab (Primary) ; 129 Xenon
- Indications Asthma
- Focus Therapeutic Use
- Acronyms AERFLO
- 10 May 2023 Planned End Date changed from 1 Jan 2023 to 18 Jan 2025.
- 11 Feb 2023 Results assessing the VDP responses at 28-days persist and do FEV(1), FeNO and mucus-plug score improve during a 2.5-year treatment period, published in the Chest.
- 12 Oct 2022 Planned End Date changed from 1 Jan 2021 to 1 Jan 2023.